cAMPfield Therapeutics

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
PDE4Small molecule
Psoriasis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 October 2026Topline resultHPP737Prifemilast Phase 3 head-to-head vs apremilast (NCT07712731) met both co-primary endpoints
China · cAMPfield Therapeutics (Newsoara's ex-Greater China licensee) · Source ↗

Financial reports

No financial reports recorded.